Decades of strong science shows that medication abortion care is safe and effective. The Society advocates for policies and practices that advance accessible, equitable, and person-centered medication abortion care and that are grounded in rigorous research demonstrating its safety and efficacy. Read more about how the Society advocates, uplifts the science, and produces clinical guidance to support in implementing best practices.

Advocacy

The Society advocates for medication abortion practices and policies grounded in science by:

Calling for the federal Food and Drug Administration’s (FDA) mifepristone labelling to reflect the evidence base and clinical best practices

• Citizen Petition requesting that the FDA remove remaining restrictions on mifepristone
• Citizen Petition urging the FDA to add miscarriage to the label for mifepristone
• Letter urging the FDA to communicate their plans to handle interference with mifepristone’s approval and encouraging them to preserve and enhance access to mifepristone
• Letter urging the FDA to consider the evidence in its review of the Risk Evaluation and Mitigation Strategy (REMS) for mifepristone

Defending against legislation, laws, and regulations that further restrict or ban access to medication abortion

• Statements and legal briefs defending against legal action to rescind FDA approval of mifepristone
• Amicus brief in Bryant v Stein, challenging North Carolina’s restrictions on mifepristone

Combatting mis- and disinformation about medication abortion

• Letter to the Food and Drug Administration urging it to reject scientifically unsupported claims and instead uphold the overwhelming evidence demonstrating mifepristone’s safety and efficacy
• Letter to the Colorado Medical Board urging them to follow the science and protect pregnant people by acknowledging “abortion reversal” is not accepted standard medical practice

Research

In pursuit of our vision of just and equitable abortion informed by science, the Society supports and uplifts research regarding the safety and efficacy of medication abortion.

• Increasing access to medication abortion
• Innovations in medication abortion service delivery
• Capturing tradeoffs in abortion care
• Science Says: Telehealth medication abortion is safe and effective
• #WeCount quarterly reports on the changes in abortion volumes following the Dobbs ruling

Clinical Guidance

To support clinicians who administer medication abortion, the Society provides evidence-informed and person-centered guidance. 

• Medication abortion up to 70 days of gestation
• Medication management for early pregnancy loss
• Clinical Recommendation: Medication abortion between 14 0/7 and 27 6/7 weeks of gestation
• Medication abortion with misoprostol-only: A sample protocol (endorsed)
• Interim Clinical Recommendation: Self-managed abortion
• Self-managed abortion (ACOG)

Learning

The Society supports ongoing learning about medication abortion for clinicians, scholars, and advocates.

• Source for Science Podcast: Clinician perspectives on self-managed abortion
• Self-managed abortion: What clinicians need to know – Course (Login Required)
• Misoprostol alone for medication abortion: A safe and effective option – Course (Login Required)
• Misoprostol-only medication abortion regimens are safe and effective across a range of gestational durations – Graphic
• Medication abortion between 14 0/7 and 27 6/7 weeks of gestation – Course (Members Only)
• Clinical guidance slide decks (Members Only)
• Abortion Pill CME